Pharma crops DTC spending by 8%

We all know that pharma has been cutting back its consumer advertising--and here's how. Drugmakers slashed ad spending by 8 percent last year to $4.4 billion from a peak of $4.8 billion in 2007. It's the first time pharma has backed away from DTC in at least a decade. (And yes, you can practically hear TV networks and magazine publishers weeping.)

Of course, $4.4 billion is still way, way more than drugmakers were spending on consumer ads 10 years back. IMS Health says pharma ads ran to less than $1 billion in 1997.

Marketing types say spending fell because fewer new meds hit the market during 2008, and because regulators--and politicians--had trained their eagle eyes on drug marketing, the Wall Street Journal reports. Case in point: the Merck/Schering-Plough drug Vytorin, which came under Congressional scrutiny after a long-delayed (and less than flattering) clinical trial came to light. M/S-P slashed Vytorin ad spending to $47 million from $114 million.

Print advertising fell the most--by 18 percent--while TV ad spending dropped by 4 percent. And pharma's 8 percent ad cutback outpaced the overall decline in ad spending, which amounted to 2.6 percent.

- read the WSJ story

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.